Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $121.3 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 287.94% year-over-year to $121.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $495.3 million (up 176.43% YoY) and the FY2025 annual result came in at $405.3 million, up 90.35% from the prior year.
• Change in Acquisitions & Divestments fell to $121.3 million in Q1 2026 per JANX's latest filing, from $152.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $152.9 million in Q4 2025 and bottomed at $31.3 million in Q1 2025.
• The 5-year median for Change in Acquisitions & Divestments is $77.1 million (2022), against an average of $81.0 million.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments jumped 427.21%; it then plunged 52.89% in 2024.
• Tracing JANX's Change in Acquisitions & Divestments over 5 years: stood at $86.5 million in 2022, then tumbled by 48.27% to $44.8 million in 2023, then gained by 29.61% to $58.0 million in 2024, then jumped by 163.67% to $152.9 million in 2025, then dropped by 20.67% to $121.3 million in 2026.
• Per Business Quant, the three latest JANX Change in Acquisitions & Divestments figures stand at $121.3 million (Q1 2026), $152.9 million (Q4 2025), and $126.4 million (Q3 2025).

Peer Comparison